

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

CONTINUING CONNECTED TRANSACTIONS

ENTERING INTO THE 2024 WATER ELECTRICITY FRAMEWORK AGREEMENT, THE 2024 LABOUR SERVICES FRAMEWORK AGREEMENT, THE 2024 LEASING ASSETS FRAMEWORK AGREEMENT AND THE 2024 PURCHASE FRAMEWORK AGREEMENT WITH LIVZON MAB

Entering into the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement with Livzon MAB

On 29 December 2023, the Company convened a Board meeting to consider and approve the continuing connected transactions for the period from 1 January 2024 to 31 December 2024 in relation to (1) provision of water, electricity, steam and sewage treatment to Livzon MAB by the Group, (2) provision of labour services to Livzon MAB by the Group, (3) leasing assets to Livzon MAB by the Group and (4) purchasing drugs from Livzon MAB by the Group, with an annual cap of RMB33.00 million, RMB42.50 million, RMB39.00 million and RMB76.00 million, respectively. On the same day, the Company and Livzon MAB entered into the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement in relation to the above-mentioned continuing connected transactions, respectively.

Implications of the Hong Kong Listing Rules

As at the date of this announcement, Joicare directly and indirectly owns approximately 45.34% equity interests in the Company, therefore it is the controlling shareholder of the Company. Joicare indirectly owns 33.07% equity interests in Livzon MAB, therefore Livzon MAB is an associate of Joicare. Therefore, Joicare and its associates and Livzon MAB are the connected persons of the Company and the transactions contemplated under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Hong Kong Listing Rules, respectively. As (i) Mr. Zhu Baoguo, a non-executive Director and the chairman of the Company, is also the chairman of Joicare and indirectly holds 48.01% equity interest in Joicare as at the date of this announcement; (ii) Mr. Qiu Qingfeng, a non-executive Director, is a director and a vice president of Joicare; (iii) Mr. Yu Xiong, a non-executive

Director, is the president and a director of Joincare; and (iv) Mr. Tang Yanggang, an executive Director, and Mr. Tao Desheng, a non-executive Director, are also the directors of Livzon MAB, therefore Mr. Zhu Baoguo, Mr. Qiu Qingfeng, Mr. Yu Xiong, Mr. Tang Yanggang and Mr. Tao Desheng are deemed to have material interests in the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement and the transactions contemplated thereunder, and have abstained from voting at the Board meeting in relation to the approval of the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement and the transactions contemplated thereunder. Except for Mr. Zhu Baoguo, Mr. Qiu Qingfeng, Mr. Yu Xiong, Mr. Tang Yanggang and Mr. Tao Desheng, no other Directors are required to abstain from voting at the Board meeting in relation to the above matters.

As the highest applicable percentage ratios of the 2024 Water Electricity Cap, the 2024 Labour Services Cap, the 2024 Lease Cap and the 2024 Purchase Cap are higher than 0.1% but lower than 5%, respectively, the transactions contemplated under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement are subject to the reporting and announcement requirements, but are exempted from the Shareholders' approval requirements under Chapter 14A of the Hong Kong Listing Rules.

I. 2024 WATER ELECTRICITY FRAMEWORK AGREEMENT

On 29 December 2023, the Company and Livzon MAB entered into the 2024 Water Electricity Framework Agreement in relation to the continuing connected transactions for provision of water, electricity, steam and sewage treatment to Livzon MAB by the Group for the period from 1 January 2024 to 31 December 2024, with an annual cap of RMB33.00 million.

Date

29 December 2023

Parties

Purchaser: Livzon MAB

Seller: the Company

Term

From 1 January 2024 to 31 December 2024

Conditions precedent

The 2024 Water Electricity Framework Agreement and the transactions contemplated thereunder are subject to the approval of the Board.

Subject Matter

Pursuant to the 2024 Water Electricity Framework Agreement, during the period from 1 January 2024 to 31 December 2024, the Group will provide Livzon MAB with water, electricity, steam and sewage treatment. The Group may enter into specific implementation contracts (including but not limited to settlement terms and payment arrangement) with Livzon MAB in respect of provision of water, electricity, steam and sewage treatment, provided that such detailed terms of the implementation contracts shall not contravene the terms of the 2024 Water Electricity Framework Agreement.

Annual Cap and Basis of Determination

During the period from 1 January 2024 to 31 December 2024, the Group will provide Livzon MAB with water, electricity, steam and sewage treatment, with an annual cap of RMB33.00 million. The annual cap was determined by the Group and Livzon MAB on arm's length negotiations by taking into account factors such as the historical transaction amounts and Livzon MAB's expected progress in relevant drug research and development ("R&D") and production plan needs in 2024.

Historical Transaction Amounts

Unit: RMB million

For the year ended 31 December 2021 (Audited)	For the year ended 31 December 2022 (Audited)	For the eleven months ended 30 November 2023 (Unaudited)
14.22	27.87	29.01

Pricing Principles

The prices for provision of water, electricity and steam to Livzon MAB by the Group will be determined on arm's length negotiations by reference to the prevailing market prices, and the prices of sewage treatment will be calculated with reference to the volume of sewage treatment and the relevant costs of materials consumed.

Reasons and Benefits of Entering into the 2024 Water Electricity Framework Agreement

Livzon MAB requires water, electricity, steam and sewage treatment for its production and operation purposes. If Livzon MAB purchases such utilities separately from the independent third parties, it may take time for Livzon MAB to complete various procedures and formalities, which may affect its recent continuously growing production and operation, and Livzon MAB will have to pay for the relevant activation fees and bear the additional administrative costs incurred. Therefore, the provision of water, electricity, steam and sewage treatment to Livzon MAB by the Group can reduce the potential impact on the production and operation of Livzon MAB and save costs, thereby improving the overall operation performance of the Group as Livzon MAB is a controlling subsidiary of the Company.

After considering all relevant factors, the Directors (including independent non-executive Directors) considered that the 2024 Water Electricity Framework Agreement (including the proposed annual cap) was entered into by the Company on normal commercial terms in the ordinary and usual course of business of the Group, and that the terms thereof are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

II. 2024 LABOUR SERVICES FRAMEWORK AGREEMENT

On 29 December 2023, the Company and Livzon MAB entered into the 2024 Labour Services Framework Agreement in relation to the continuing connected transactions for provision of labour services to Livzon MAB by the Group for the period from 1 January 2024 to 31 December 2024, with an annual cap of RMB42.50 million.

Date

29 December 2023

Parties

Purchaser: Livzon MAB

Seller: the Company

Term

From 1 January 2024 to 31 December 2024

Conditions precedent

The 2024 Labour Services Framework Agreement and the transactions contemplated thereunder are subject to the approval of the Board.

Subject Matter

Pursuant to the 2024 Labour Services Framework Agreement, during the period from 1 January 2024 to 31 December 2024, the Group will provide Livzon MAB with commissioned production of drugs. The Group may enter into specific implementation contracts (including but not limited to settlement terms and payment arrangement) with Livzon MAB in respect of provision of labour services, provided that such detailed terms of the implementation contracts shall not contravene the terms of the 2024 Labour Services Framework Agreement.

Annual Cap and Basis of Determination

During the period from 1 January 2024 to 31 December 2024, the Group will provide Livzon MAB with commissioned production of drugs, with an annual cap of RMB42.50 million. The annual cap was determined by the Group and Livzon MAB on arm's length negotiations by taking into account factors such as volume of commissioned production and estimated production costs. The 2024 Labour Services Cap is higher than the transaction amount in previous years, mainly because it is expected that the product demand of Livzon MAB's Recombinant Human Choriogonadotropin alfa for Injection (注射用重組人絨促性素) will increase significantly, and therefore the production volume commissioned to the Group will also increase accordingly.

Historical Transaction Amounts

Unit: RMB million

For the year ended 31 December 2021	For the year ended 31 December 2022	For the eleven months ended 30 November 2023
(Audited)	(Audited)	(Unaudited)
16.95	5.92	7.77

Pricing Principles

The prices for the provision of commissioned production of drugs to Livzon MAB by the Group will be determined on arm's length negotiations by reference to factors such as the operation costs and the comparable prevailing market prices of the commissioned production.

Reasons and Benefits of Entering into the 2024 Labour Services Framework Agreement

Livzon MAB can leverage the Group's sound production experience and a long history of excellence in the production of hormone drugs, fully utilize the Group's production workshops that meet the requirements for rHCG and rFSH technique and preparation, and utilize the Group's part of surplus production capacity to optimize the capacity utilization of the production workshops of the Group. Meanwhile, Livzon MAB can focus its resources on R&D by avoiding the repeated construction of its production facilities. Therefore, the overall operation performance of the Group can be improved, as Livzon MAB is a controlling subsidiary of the Company.

After considering all relevant factors, the Directors (including independent non-executive Directors) considered that the 2024 Labour Services Framework Agreement (including the proposed annual cap) was entered into by the Company on normal commercial terms in the ordinary and usual course of business of the Group, and that the terms thereof are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

III. 2024 LEASING ASSETS FRAMEWORK AGREEMENT

On 29 December 2023, the Company and Livzon MAB entered into the 2024 Leasing Assets Framework Agreement in relation to the continuing connected transactions for leasing assets to Livzon MAB by the Group for the period from 1 January 2024 to 31 December 2024, with an annual cap of RMB39.00 million.

Date

29 December 2023

Parties

Purchaser: Livzon MAB

Seller: the Company

Term

From 1 January 2024 to 31 December 2024

Conditions precedent

The 2024 Leasing Assets Framework Agreement and the transactions contemplated thereunder are subject to the approval of the Board.

Subject Matter

Pursuant to the 2024 Leasing Assets Framework Agreement, during the period from 1 January 2024 to 31 December 2024, the Group will lease factories and equipment to Livzon MAB. The Group may enter into specific implementation contracts (including but not limited to settlement terms and payment arrangement) with Livzon MAB in respect of leasing assets, provided that such detailed terms of the implementation contracts shall not contravene the terms of the 2024 Leasing Assets Framework Agreement.

Annual Cap and Basis of Determination

During the period from 1 January 2024 to 31 December 2024, the Group will lease factories and equipment to Livzon MAB, with an annual cap of RMB39.00 million. The annual cap was determined by the Group and Livzon MAB on arm's length negotiations by taking into account factors such as the progress of R&D and production of Livzon MAB's existing product varieties, factory space and equipment required and business demand.

Historical Transaction Amounts

Unit: RMB million

For the year ended 31 December 2021	For the year ended 31 December 2022	For the eleven months ended 30 November 2023
(Audited)	(Audited)	(Unaudited)
17.73	36.28	33.19

Pricing Principles

The prices for leasing factories and equipment to Livzon MAB by the Group will be determined on arm's length negotiations by reference to factors such as the costs of operation, potential comprehensive income and the prevailing market prices of the comparable factories and equipment.

Reasons and Benefits of Entering into the 2024 Leasing Assets Framework Agreement

Livzon MAB is located in the production site of Pharmaceutical Factory and is able to carry out relevant production activities in a convenient and efficient manner by leasing of the existing factories and equipment of Pharmaceutical Factory, while the existing factories and equipment of Pharmaceutical Factory can meet Livzon MAB’s needs for its production. If Livzon MAB leases the factories and equipment from the independent third parties and outside the production site, the long distance is not conducive to the development of its production activities, and it will take time for Livzon MAB to complete various procedures and formalities, which may affect its production and operation. Therefore, leasing factories and equipment by Livzon MAB from Pharmaceutical Factory can reduce the potential impact on the production and operation of Livzon MAB and save costs, thereby improving the overall operation performance of the Group as Livzon MAB is a controlling subsidiary of the Company.

After considering all relevant factors, the Directors (including independent non-executive Directors) considered that the 2024 Leasing Assets Framework Agreement (including the proposed annual cap) was entered into by the Company on normal commercial terms in the ordinary and usual course of business of the Group, and that the terms thereof are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

IV. 2024 PURCHASE FRAMEWORK AGREEMENT

On 29 December 2023, the Company and Livzon MAB entered into the 2024 Purchase Framework Agreement in relation to the continuing connected transactions for purchasing drugs from Livzon MAB by the Group for the period from 1 January 2024 to 31 December 2024, with an annual cap of RMB76.00 million.

Date

29 December 2023

Parties

Purchaser: the Company
Seller: Livzon MAB

Term

From 1 January 2024 to 31 December 2024

Conditions precedent

The 2024 Purchase Framework Agreement and the transactions contemplated thereunder are subject to the approval of the Board.

Subject Matter

Pursuant to the 2024 Purchase Framework Agreement, during the period from 1 January 2024 to 31 December 2024, the Group will purchase drugs from Livzon MAB, primarily Tocilizumab Injection (托珠單抗注射液) and Recombinant Human Choriogonadotropin alfa for Injection (注射用重組人絨促性素). The Group may enter into specific implementation contracts (including but not limited to settlement terms and payment arrangement) with Livzon MAB in respect of purchasing drugs, provided that such detailed terms of the implementation contracts shall not contravene the terms of the 2024 Purchase Framework Agreement.

Annual Cap and Basis of Determination

During the period from 1 January 2024 to 31 December 2024, the Group will purchase drugs from Livzon MAB, primarily Tocilizumab Injection (托珠單抗注射液) and Recombinant Human Choriogonadotropin alfa for Injection (注射用重組人絨促性素), with an annual cap of RMB76.00 million. The annual cap was determined by the Group and Livzon MAB on arm's length negotiations by taking into account factors such as the estimated market demand, market selling price, and estimated sales cost of the above drugs. The 2024 Purchase Cap is higher than the transaction amount in previous years, which is mainly due to the opening up of new sales market resulting from the approval of two new indications of Tocilizumab Injection (托珠單抗注射液) in 2023 and the expected increase in market share of Recombinant Human Choriogonadotropin alfa for Injection (注射用重組人絨促性素), leading to the expected significant increase in sales of the two products in 2024.

Historical Transaction Amounts

Unit: RMB million		
For the year ended 31 December 2021	For the year ended 31 December 2022	For the eleven months ended 30 November 2023
(Audited)	(Audited)	(Unaudited)
7.88	7.14	27.33

Pricing Principles

The prices for purchasing drugs from Livzon MAB by the Group will be determined on arm's length negotiations by reference to factors such as the drugs' market selling price and estimated sales cost.

Reasons and Benefits of Entering into the 2024 Purchase Framework Agreement

Livzon MAB can leverage the Group's rich experience in the management of sales teams and advantages of sales pipeline layout and fully utilize the Group's existing sales system structure, and the Group's internal resources can be integrated, which can improve resource efficiency and reduce operating costs. Livzon MAB can focus its resources on R&D by avoiding the repeated construction of its sales teams. Therefore, the overall operation performance of the Group can be improved, as Livzon MAB is a controlling subsidiary of the Company.

After considering all relevant factors, the Directors (including independent non-executive Directors) considered that the 2024 Purchase Framework Agreement (including the proposed annual cap) was entered into by the Company on normal commercial terms in the ordinary and usual course of business of the Group, and that the terms thereof are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

V. INTERNAL CONTROL MEASURES

In order to ensure that the actual prices of the transactions contemplated under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement between the Group and Livzon MAB are on normal commercial terms and on terms no less favourable to the Group than that available from third parties, the Group adopts the following internal control procedures for its daily operation:

(i) Each transaction to be conducted under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement will be signed by the designated staff of the department requesting such transaction and the finance department, and the general manager of the relevant subsidiary and/or the president of the Company.

(ii) The Group will conduct regular checks to review and assess whether the transactions have been conducted in accordance with the terms of the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement. Such checks will be conducted by the general manager of finance of the Company on a monthly basis and the secretary of the Board on a quarterly basis and will be reported to the Board.

(iii) To ensure the continuing connected transactions contemplated under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement will not exceed the annual caps, each subsidiary will submit monthly financial figures to the financial department of the Company for consolidation and analysis. The Group will conduct transactions in accordance with the annual plan which is formulated by the finance department of the Group at the year end of the preceding year and is subject to quarterly review. In particular, the finance department of the Company is responsible for monitoring the actual transactions amounts between the Group and Livzon MAB on a monthly basis to ensure that the annual caps will not be exceeded. In the event the amount of continuing connected transactions incurred and to be incurred under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement is expected to exceed the annual caps, the general manager of finance of the Company shall report to the management of the Company in a timely manner for its determination as to whether revision to the annual caps is required to ensure compliance of the requirements under the Hong Kong Listing Rules.

(iv) The relevant departments and the finance department of the Company will review the internal pricing policy or mechanism, provisions and implementation status with respect to the continuing connected transactions on an annual basis, including but not limited to identifying the connected persons of the Group and their processes for handling the continuing connected transactions. In the event that the relevant departments consider adjustment to the pricing policy or mechanism is required, they shall make amendment proposals with detailed reasons and supporting materials for the management of the Company to consider and determine appropriate actions to be taken.

(v) The auditor of the Company will conduct an annual review of the transactions contemplated under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement.

(vi) The audit committee of the Company shall review the continuing connected transactions contemplated under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement twice a year to confirm whether the relevant transactions are on fair and reasonable terms and in the interest of the Company and the Shareholders as a whole.

Having considered the internal control measures mentioned above, the Directors (including the independent non-executive Directors) consider that such internal control measures are sufficient to ensure the transactions contemplated under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement will be entered into on normal commercial terms, and will not impair the interests of the Company and the Shareholders as a whole.

VI. INFORMATION OF THE PARTIES

The Company, through its subsidiaries, is principally engaged in the R&D, production and sales of drug preparation products, active pharmaceutical ingredients and intermediates, as well as diagnostic reagents and equipment.

Livzon MAB is a company incorporated in the PRC with limited liability and is principally engaged in research, development and commercialization of biopharmaceutical products. Its ultimate beneficial owner is Mr. Zhu Baoguo, a non-executive Director and the chairman of the Company.

VII. IMPLICATIONS OF THE HONG KONG LISTING RULES

As at the date of this announcement, Joincare directly and indirectly owns approximately 45.34% equity interests in the Company, therefore it is the controlling shareholder of the Company. Joincare indirectly owns 33.07% equity interests in Livzon MAB, therefore Livzon MAB is an associate of Joincare. Therefore, Joincare and its associates and Livzon MAB are the connected persons of the Company and the transactions contemplated under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Hong Kong Listing Rules, respectively. As (i) Mr. Zhu Baoguo, a non-executive Director and the chairman of the Company, is also the chairman of Joincare and indirectly holds 48.01% equity interest in Joincare as at the date of this announcement; (ii) Mr. Qiu Qingfeng,

a non-executive Director, is a director and a vice president of Joincare; (iii) Mr. Yu Xiong, a non-executive Director, is the president and a director of Joincare; and (iv) Mr. Tang Yanggang, an executive Director, and Mr. Tao Desheng, a non-executive Director, are also the directors of Livzon MAB, therefore Mr. Zhu Baoguo, Mr. Qiu Qingfeng, Mr. Yu Xiong, Mr. Tang Yanggang and Mr. Tao Desheng are deemed to have material interests in the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement and the transactions contemplated thereunder, and have abstained from voting at the Board meeting in relation to the approval of the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement and the transactions contemplated thereunder. Except for Mr. Zhu Baoguo, Mr. Qiu Qingfeng, Mr. Yu Xiong, Mr. Tang Yanggang and Mr. Tao Desheng, no other Directors are required to abstain from voting at the Board meeting in relation to the above matters.

As the highest applicable percentage ratios of the 2024 Water Electricity Cap, the 2024 Labour Services Cap, the 2024 Lease Cap and the 2024 Purchase Cap are higher than 0.1% but lower than 5%, respectively, the transactions contemplated under the 2024 Water Electricity Framework Agreement, the 2024 Labour Services Framework Agreement, the 2024 Leasing Assets Framework Agreement and the 2024 Purchase Framework Agreement are subject to the reporting and announcement requirements, but are exempted from the Shareholders' approval requirements under Chapter 14A of the Hong Kong Listing Rules.

DEFINITIONS

In this announcement, the following expressions shall have the meanings set out below unless the context requires otherwise:

“2024 Labour Services Cap”	The annual cap of RMB42.50 million regarding the Group’s provision of labour services to Livzon MAB during the period from 1 January 2024 to 31 December 2024
“2024 Labour Services Framework Agreement”	The framework agreement entered into between the Company and Livzon MAB on 29 December 2023 in relation to the continuing connected transaction regarding provision of labour services to Livzon MAB by the Group for the period from 1 January 2024 to 31 December 2024, with an annual cap of RMB42.50 million
“2024 Lease Cap”	The annual cap of RMB39.00 million regarding the Group’s leasing assets to Livzon MAB during the period from 1 January 2024 to 31 December 2024

“2024 Leasing Assets Framework Agreement”	The framework agreement entered into between the Company and Livzon MAB on 29 December 2023 in relation to the continuing connected transaction regarding leasing assets to Livzon MAB by the Group for the period from 1 January 2024 to 31 December 2024, with an annual cap of RMB39.00 million
“2024 Purchase Cap”	The annual cap of RMB76.00 million regarding the Group’s purchase of drugs from Livzon MAB during the period from 1 January 2024 to 31 December 2024
“2024 Purchase Framework Agreement”	The framework agreement entered into between the Company and Livzon MAB on 29 December 2023 in relation to the continuing connected transaction regarding purchasing drugs from Livzon MAB by the Group for the period from 1 January 2024 to 31 December 2024, with an annual cap of RMB76.00 million
“2024 Water Electricity Cap”	The annual cap of RMB33.00 million regarding the Group’s provision of water, electricity, steam and sewage treatment to Livzon MAB during the period from 1 January 2024 to 31 December 2024
“2024 Water Electricity Framework Agreement”	The framework agreement entered into between the Company and Livzon MAB on 29 December 2023 in relation to the continuing connected transaction regarding provision of water, electricity, steam and sewage treatment to Livzon MAB by the Group for the period from 1 January 2024 to 31 December 2024, with an annual cap of RMB33.00 million
“associate(s)”	has the meaning ascribed to it under the Hong Kong Listing Rules
“Board”	the board of Directors
“Company”	Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司), a joint stock company incorporated in the PRC with limited liability, the Shares of which are listed on the Shenzhen Stock Exchange and the Stock Exchange
“connected person(s)”	has the meaning ascribed to it under the Hong Kong Listing Rules
“controlling shareholder(s)”	has the meaning ascribed to it under the Hong Kong Listing Rules

“Director(s)”		the director(s) of the Company
“Group”		collectively the Company and its subsidiaries
“Hong Kong”		Hong Kong Special Administrative Region of the PRC
“Hong Kong Listing Rules”		The Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited, as amended and supplemented or otherwise modified from time to time
“independent third party (ies)”		a person or persons or a company or companies that is not or are not the connected person(s) of the Group
“Joincare”		Joincare Pharmaceutical Industry Group Co., Ltd.* (健康元藥業集團股份有限公司) (Shanghai Stock Exchange stock code: 600380), a joint stock company incorporated in the PRC and listed on the Shanghai Stock Exchange in 2001, and is a controlling shareholder of the Group
“Livzon MAB”		Livzon MABPharm Inc.* (珠海市麗珠單抗生物技術有限公司), a subsidiary indirectly owned as to 51.00% by the Company, which is a limited liability company established in the PRC in 2010
“Pharmaceutical Factory”		Livzon Group Livzon Pharmaceutical Factory* (麗珠集團麗珠製藥廠), a wholly-owned subsidiary of the Company, which is a limited liability company established in the PRC in 1989
“PRC”		the People’s Republic of China, excluding Hong Kong, Macau Special Administrative Region of the PRC and Taiwan for the purpose of this announcement
“RMB”		Renminbi, the lawful currency of the PRC
“Shanghai Exchange”	Stock	the Shanghai Stock Exchange (上海證券交易所)
“Shareholder(s)”		holder(s) of the share(s) of the Company
“Shenzhen Exchange”	Stock	the Shenzhen Stock Exchange (深圳證券交易所)
“Stock Exchange”		The Stock Exchange of Hong Kong Limited
“%”		per cent

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China

29 December 2023

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*